Ceregene, Inc. Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study
5/21/2013 10:17:28 AM
More...
|
Ceregene, Inc. Reports Data From Parkinson's Disease Phase 2b Study
4/22/2013 9:56:37 AM
More...
|
Ceregene, Inc. and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial
3/13/2013 9:49:03 AM
More...
|
Ceregene, Inc. Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5/17/2012 1:01:13 PM
More...
|
Ceregene, Inc. Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease
12/1/2011 12:29:34 PM
More...
|
Ceregene, Inc. Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors
2/15/2011 7:22:25 AM
More...
|
Ceregene, Inc. Advances Phase 2b CERE-120 (AAV2-neurturin) Trial in Parkinson's Disease
2/3/2011 7:12:49 AM
More...
|
Ceregene, Inc. Raises $11.5 Million in Series D Financing
11/11/2010 6:20:30 AM
More...
|
Ceregene, Inc. Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
10/20/2010 7:40:43 AM
More...
|
Ceregene, Inc. Initiates a New Controlled Phase 2b Trial of Cere-120 for Parkinson's Disease
10/19/2010 1:18:25 PM
More...
|
|